Celularity is a clinical-stage biotechnology company focusing on the next evolution in cellular medicine by developing off-the-shelf placenta-derived allogeneic cell therapies, including genetically modified natural killer (NK) cells and T cells engineered with a chimeric antigen receptor (CAR-T cells) that target indications across cancer as well as infectious and degenerative diseases . . .
- Cancer
- T Cells
- CAR T-Cells
- Cell Therapy
- Drug Discovery
- Financing
- GEN Edge
- Translational Medicine
- Infectious Diseases
Celularity: Productizing Placental-Derived Stem Cells for Any Patient
Built on 20 years of research legacy and now public courtesy of a SPAC, this New Jersey-based clinical-stage biotechnology company is developing off-the-shelf allogeneic cell therapies.
[Source: Jezperklauzen / Getty Images]